Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Survivorship
Published in: Journal of Cancer Survivorship 4/2021

Open Access 01-08-2021 | Fatigue

Body composition and its association with fatigue in the first 2 years after colorectal cancer diagnosis

Authors: H. van Baar, M. J. L. Bours, S. Beijer, M. van Zutphen, F. J. B. van Duijnhoven, D. E. Kok, E. Wesselink, J. H. W. de Wilt, E. Kampman, R. M. Winkels

Published in: Journal of Cancer Survivorship | Issue 4/2021

Login to get access

Abstract

Purpose

Persistent fatigue among colorectal cancer (CRC) patients might be associated with unfavorable body composition, but data are sparse and inconsistent. We studied how skeletal muscle index (SMI), skeletal muscle radiodensity (SMR), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) at diagnosis are associated with fatigue up to 24 months post-diagnosis in stage I–III CRC patients.

Methods

SMI, SMR, VAT, and SAT were assessed among 646 CRC patients using pre-treatment computed tomography images. Fatigue at diagnosis, at 6, and 24 months post-diagnosis was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. The association of SMI, SMR, VAT, and SAT with fatigue (yes/no) was assessed using confounder-adjusted restricted cubic spline analyses.

Results

Prevalence of fatigue at diagnosis was 18%, at 6 months 25%, and at 24 months 12%. At diagnosis, a significant (p = 0.01) non-linear association of higher levels of SAT with higher prevalence of fatigue was observed. Lower levels of SMR were linearly associated with higher prevalence of fatigue at 6 months post-diagnosis (overall association p = 0.02). None of the body composition parameters were significantly associated with fatigue at 24 months.

Conclusion

Having more SAT was associated with more fatigue at diagnosis, while low levels of SMR were associated with more fatigue at 6 months post-diagnosis.

Implications for Cancer Survivors

Our results suggest that it may be interesting to investigate whether interventions that aim to increase SMR around the time of diagnosis may help to lower fatigue. However, more knowledge is needed to understand the mechanisms behind the association of SMR with fatigue.
Appendix
Available only for authorised users
Literature
1.
Hickok JT, Roscoe JA, Morrow GR, Mustian K, Okunieff P, Bole CW. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer. 2005;104(8):1772–8.PubMed
2.
Bower JE. Cancer-related fatigue—mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11(10):597–609.PubMedPubMedCentral
3.
Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12(Supplement 1):4–10.PubMed
4.
Thong MS, Mols F, Wang XS, Lemmens VE, Smilde TJ, van de Poll-Franse LV. Quantifying fatigue in (long-term) colorectal cancer survivors: a study from the population-based patient reported outcomes following initial treatment and long term evaluation of survivorship registry. Eur J Cancer. 2013;49(8):1957–66.PubMedPubMedCentral
5.
Mitchell SA. Cancer-related fatigue: state of the science. PM&R. 2010;2(5):364–83.
6.
Aapro M, Scotte F, Bouillet T, Currow D, Vigano A. A practical approach to fatigue management in colorectal cancer. Clin Colorectal Cancer. 2017;16(4):275–85.PubMed
7.
Vissers PAJ, Thong MSY, Pouwer F, Zanders MMJ, Coebergh JWW, van de Poll-Franse LV. The impact of comorbidity on Health-Related Quality of Life among cancer survivors: analyses of data from the PROFILES registry. J Cancer Surviv. 2013;7(4):602–13.PubMed
8.
Schmidt ME, Chang-Claude J, Seibold P, Vrieling A, Heinz J, Flesch-Janys D, et al. Determinants of long-term fatigue in breast cancer survivors: results of a prospective patient cohort study. Psycho-Oncology. 2015;24(1):40–6.PubMed
9.
Courneya KS, Karvinen KH, Campbell KL, Pearcey RG, Dundas G, Capstick V, et al. Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. Gynecol Oncol. 2005;97(2):422–30.PubMed
10.
Oldenburg CS, Boll D, Nicolaije KA, Vos MC, Pijnenborg JM, Coebergh J-W, et al. The relationship of body mass index with quality of life among endometrial cancer survivors: a study from the population-based PROFILES registry. Gynecol Oncol. 2013;129(1):216–21.PubMed
11.
van Veen MR, Mols F, Bours MJ, Weijenberg MP, Kampman E, Beijer S. Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations for cancer prevention is associated with better health–related quality of life among long-term colorectal cancer survivors: results of the PROFILES registry. Support Care Cancer. 2019;27(12):4565–74.PubMedPubMedCentral
12.
Smits A, Lopes A, Das N, Bekkers R, Galaal K. The impact of BMI on quality of life in obese endometrial cancer survivors: does size matter? Gynecol Oncol. 2014;132(1):137–41.PubMed
13.
Basen-Engquist K, Scruggs S, Jhingran A, Bodurka DC, Lu K, Ramondetta L, et al. Physical activity and obesity in endometrial cancer survivors: associations with pain, fatigue, and physical functioning. Am J Obstet Gynecol. 2009;200(3):288. e1–8.
14.
Burkhauser RV, Cawley J. Beyond BMI: the value of more accurate measures of fatness and obesity in social science research. J Health Econ. 2008;27(2):519–29.PubMed
15.
Bye A, Sjøblom B, Wentzel-Larsen T, Grønberg BH, Baracos VE, Hjermstad MJ, et al. Muscle mass and association to quality of life in non-small cell lung cancer patients. J Cachexia Sarcopenia Muscle. 2017;8(5):759–67.PubMedPubMedCentral
16.
Neefjes ECW, Hurk RM, Blauwhoff-Buskermolen S, Vorst MJDL, Becker-Commissaris A, Schueren MAE, et al. Muscle mass as a target to reduce fatigue in patients with advanced cancer. J Cachexia Sarcopenia Muscle. 2017;8(4):623–9.PubMedPubMedCentral
17.
van Roekel EH, Bours MJL, te Molder MEM, Breedveld-Peters JJL, Olde Damink SWM, Schouten LJ, et al. Associations of adipose and muscle tissue parameters at colorectal cancer diagnosis with long-term health-related quality of life. Qual Life Res. 2017;26(7):1745–59.PubMedPubMedCentral
18.
Winkels R, Heine-Broring R, Van Zutphen M, van Harten-Gerritsen S, Kok D, Van Duijnhoven F, et al. The COLON study: Colorectal cancer: Longitudinal, Observational study on Nutritional and lifestyle factors that may influence colorectal tumour recurrence, survival and quality of life. BMC Cancer. 2014;14(1):374.PubMedPubMedCentral
19.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.PubMed
20.
Giesinger JM, Kuijpers W, Young T, Tomaszewski KA, Friend E, Zabernigg A, et al. Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain. Health Qual Life Outcomes. 2016;14:87.PubMedPubMedCentral
21.
Giesinger JM, Loth FL, Aaronson NK, Arraras JI, Caocci G, Efficace F, et al. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol. 2020;118:1–8.PubMed
22.
Prado CMM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care. 2009;3(4):269–75.PubMed
23.
Mitsiopoulos N, Baumgartner R, Heymsfield S, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85(1):115–22.PubMed
24.
Wendel-Vos GW, Schuit AJ, Saris WH, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol. 2003;56(12):1163–9.PubMed
25.
Van Leersum N, Snijders H, Henneman D, Kolfschoten N, Gooiker G, Ten Berge M, et al. The Dutch surgical colorectal audit. Eur J Surg Oncol. 2013;39(10):1063–70.PubMed
26.
Ganz PA. Impact of tamoxifen on adjuvant therapy symptoms, functioning and quality of life. J Natl Cancer Inst Monogr. 2001;(30):130–4.
27.
Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010;29(9):1037–57.PubMed
28.
Tamhane AR, Westfall AO, Burkholder GA, Cutter GR. Prevalence odds ratio versus prevalence ratio: choice comes with consequences. Stat Med. 2016;35(30):5730–5.PubMedPubMedCentral
29.
Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med. 2011;62:265–79.PubMed
30.
Williams GR, Deal AM, Muss HB, Weinberg MS, Sanoff HK, Nyrop KA, et al. Skeletal muscle measures and physical function in older adults with cancer: sarcopenia or myopenia? Oncotarget. 2017;8(20):33658–65.PubMedPubMedCentral
31.
Sjøblom B, Grønberg BH, Wentzel-Larsen T, Baracos VE, Hjermstad MJ, Aass N, et al. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clin Nutr. 2016;35(6):1386–93.PubMed
32.
Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watadani T, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015;63(1):131–40.PubMed
33.
Rier HN, Jager A, Sleijfer S, van Rosmalen J, Kock MC, Levin M-D. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast. 2017;31:9–15.PubMed
34.
van Dijk DP, Bakens MJ, Coolsen MM, Rensen SS, van Dam RM, Bours MJ, et al. Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017;8(2):317–26.PubMed
35.
Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA, Den Braver NR, Berkhof J, Langius JA, et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(12):1339–44.PubMed
36.
Ebadi M, Martin L, Ghosh S, Field CJ, Lehner R, Baracos VE, et al. Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer. 2017;117(1):148–55.PubMedPubMedCentral
37.
Antoun S, Lanoy E, Iacovelli R, Albiges-Sauvin L, Loriot Y, Merad-Taoufik M, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119(18):3377–84.PubMed
38.
van Baar H, Beijer S, Bours M, Weijenberg M, van Zutphen M, van Duijnhoven F, et al. Low radiographic muscle density is associated with lower overall and disease-free survival in early-stage colorectal cancer patients. J Cancer Res Clin Oncol. 2018:1–9.
39.
Van Hollebeke RB, Cushman M, Schlueter EF, Allison MA. Abdominal muscle density is inversely related to adiposity inflammatory mediators. Med Sci Sports Exerc. 2018;50(7):1495–501.PubMedCentral
40.
Margadant C, Bruns E, Sloothaak D, van Duijvendijk P, van Raamt A, van der Zaag H, et al. Lower muscle density is associated with major postoperative complications in older patients after surgery for colorectal cancer. Eur J Surg Oncol. 2016;42(11):1654–9.PubMed
41.
Xiao J, Caan BJ, Weltzien E, Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, et al. Associations of pre-existing co-morbidities with skeletal muscle mass and radiodensity in patients with non-metastatic colorectal cancer. J Cachexia Sarcopenia Muscle. 2018;9(4):654–63.PubMedPubMedCentral
42.
Cooper R, Popham M, Santanasto AJ, Hardy R, Glynn NW, Kuh D. Are BMI and inflammatory markers independently associated with physical fatigability in old age? Int J Obes. 2019;43(4):832–41.
43.
Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11(1):11–8.PubMed
44.
Thomas EL, Bell JD. Influence of undersampling on magnetic resonance imaging measurements of intra-abdominal adipose tissue. Int J Obes. 2003;27(2):211–8.
45.
Shuster A, Patlas M, Pinthus JH, Mourtzakis M. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol. 2012;85(1009):1–10.PubMedPubMedCentral
46.
Metadata
Title
Body composition and its association with fatigue in the first 2 years after colorectal cancer diagnosis
Authors
H. van Baar
M. J. L. Bours
S. Beijer
M. van Zutphen
F. J. B. van Duijnhoven
D. E. Kok
E. Wesselink
J. H. W. de Wilt
E. Kampman
R. M. Winkels
Publication date
01-08-2021
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 4/2021
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-020-00953-0

Other articles of this Issue 4/2021

Journal of Cancer Survivorship 4/2021 Go to the issue

OriginalPaper

Feasibility of a behavioral intervention using mobile health applications to reduce cardiovascular risk factors in cancer survivors: a pilot randomized controlled trial

OriginalPaper

Sedentary behavior among breast cancer survivors: a longitudinal study using ecological momentary assessments

Review

Evolving landscape of cancer survivorship research: an analysis of the Journal of Cancer Survivorship, 2007–2020

OriginalPaper

Hematological cancer survivors’ experiences of participating in a shared care follow-up—an exploratory interview study

Original Research

Fear of cancer recurrence among young adult cancer survivors—exploring long-term contributing factors in a large, population-based cohort

OriginalPaper

Lifestyle intervention for Latina cancer survivors and caregivers: the Nuestra Salud randomized pilot trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits